CL2019000366A1 - Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. - Google Patents

Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.

Info

Publication number
CL2019000366A1
CL2019000366A1 CL2019000366A CL2019000366A CL2019000366A1 CL 2019000366 A1 CL2019000366 A1 CL 2019000366A1 CL 2019000366 A CL2019000366 A CL 2019000366A CL 2019000366 A CL2019000366 A CL 2019000366A CL 2019000366 A1 CL2019000366 A1 CL 2019000366A1
Authority
CL
Chile
Prior art keywords
col6a3
antigen
new
tcr
nucleic acids
Prior art date
Application number
CL2019000366A
Other languages
English (en)
Inventor
Dominik Maurer
Leonie Alten
Sebastian Bunk
Steffen Walter
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102016115246.3A external-priority patent/DE102016115246C5/de
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2019000366A1 publication Critical patent/CL2019000366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN ATAÑE A CONSTRUCTOS QUE RECONOCEN ANTÍGENOS, EN CONCRETO ANTÍGENOS DE COL6A3. LA INVENCIÓN PROPORCIONA EN CONCRETO MOLÉCULAS BASADAS EN UN NUEVO RECEPTOR DE LINFOCITOS T (TCR) QUE SON SELECTIVAS Y ESPECÍFICAS HACIA EL ANTÍGENO TUMORAL COL6A3.EL TCR DE LA INVENCIÓN, ASÍ COMO LOS FRAGMENTOS QUE SE UNEN AL ANTÍGENO DE COL6A3 Y QUE DERIVAN DEL MISMO, ESTÁN DESTINADOS AL DIAGNÓSTICO, EL TRATAMIENTO Y LA PREVENCIÓN DE LAS ENFERMEDADES TUMORALES QUE EXPRESAN EL COL6A3. ADEMÁS SE PROPORCIONAN ÁCIDOS NUCLEICOS QUE CODIFICAN LOS CONSTRUCTOS RECONOCEDORES DEL ANTÍGENO DE LA INVENCIÓN, LOS VECTORES QUE COMPRENDEN ESOS ÁCIDOS NUCLEICOS, LAS CÉLULAS RECOMBINANTES QUE EXPRESAN LOS CONSTRUCTOS RECONOCEDORES DEL ANTÍGENO Y LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA INVENCIÓN.
CL2019000366A 2016-08-17 2019-02-12 Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. CL2019000366A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376059P 2016-08-17 2016-08-17
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
US201662376632P 2016-08-18 2016-08-18

Publications (1)

Publication Number Publication Date
CL2019000366A1 true CL2019000366A1 (es) 2019-07-05

Family

ID=67440460

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000366A CL2019000366A1 (es) 2016-08-17 2019-02-12 Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.

Country Status (4)

Country Link
US (2) US10800845B2 (es)
CL (1) CL2019000366A1 (es)
PH (1) PH12019500312A1 (es)
ZA (1) ZA201900664B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023382A2 (en) 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagen vi and cancer
US7820174B2 (en) * 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
US9228007B1 (en) 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
JP5617040B2 (ja) 2012-02-24 2014-10-29 株式会社クラレ ゴム組成物及びタイヤ
ES2745472T3 (es) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
US10066002B2 (en) 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
KR20250052472A (ko) * 2017-11-06 2025-04-18 이매틱스 바이오테크놀로지스 게엠베하 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법

Also Published As

Publication number Publication date
PH12019500312A1 (en) 2019-12-16
ZA201900664B (en) 2021-09-29
US20200385468A1 (en) 2020-12-10
US11939376B2 (en) 2024-03-26
US20190284276A1 (en) 2019-09-19
US10800845B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
CL2019000366A1 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
CR20190095A (es) Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
CO2019011688A2 (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
CL2019003885A1 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos.
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
CL2017000836A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer.
CL2019001535A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
BR112021019411A2 (pt) Métodos para a produção de células car-nk e uso das mesmas
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX360497B (es) Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos.
CU20170023A7 (es) Anticuerpos y receptores de antígeno quiméricos específicos para cd19
MX2018004531A (es) Proteinas de union a antigeno que activan el receptor de leptina.
CL2020001726A1 (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
MX2018013081A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
PE20250392A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
CL2018002610A1 (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
BR112019020386A2 (pt) vacinas de peptídeos de pd-1 humana e usos das mesmas
CO2019002229A2 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos